Literature DB >> 9790989

Osteoclastogenesis inhibitory factor (OCIF) directly inhibits bone-resorbing activity of isolated mature osteoclasts.

Y Hakeda1, Y Kobayashi, K Yamaguchi, H Yasuda, E Tsuda, K Higashio, T Miyata, M Kumegawa.   

Abstract

Osteoclastogenesis inhibitory factor (OCIF) was previously reported to specifically inhibit osteoclast development by interrupting the action of osteoclast differentiation factor (ODF), which is expressed in stromal cells and plays an important role in osteoclastogenesis. Here we report the direct action of OCIF on isolated rabbit mature osteoclasts to inhibit their functional bone-resorbing activity. The cell population employed in this study consisted of mature osteoclasts with more than 95% of purity. The inhibition by OCIF was dose dependent and observed as early as 6 h after the OCIF addition. An OCIF-binding protein of 140 kDa was detected on the plasma membrane of osteoclasts. ODF with a Mr of 40 kDa was recently isolated as a ligand for OCIF and shows to be identical to TRANCE/RANKL. However, ODF was not detected in osteoclasts. OCIF did not have any impact on the mRNA levels of cathepsin K/OC2 and carbonic anhydrase II responsible for degradation of organic and inorganic bone matrices, respectively, or on osteoclast apoptosis. However, OCIF reduced or disrupted the formation of F-actin ring in isolated osteoclasts, the cytoskeletal structure of which is correlated with bone resorption. These findings demonstrate that OCIF directly inhibits osteoclast function through an ODF-independent mechanism besides blocking the generation of osteoclasts. Copyright 1998 Academic Press.

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 9790989     DOI: 10.1006/bbrc.1998.9523

Source DB:  PubMed          Journal:  Biochem Biophys Res Commun        ISSN: 0006-291X            Impact factor:   3.575


  18 in total

Review 1.  Osteoprotegerin.

Authors:  U Feige
Journal:  Ann Rheum Dis       Date:  2001-11       Impact factor: 19.103

2.  Hepatic osteodystrophy: does the osteoprotegerin/receptor activator of nuclear factor-kB ligand system play a role?

Authors:  A Gaudio; A Lasco; N Morabito; M Atteritano; C Vergara; A Catalano; W Fries; A Trifiletti; N Frisina
Journal:  J Endocrinol Invest       Date:  2005-09       Impact factor: 4.256

3.  Osteoprotegerin serum levels in women: correlation with age, bone mass, bone turnover and fracture status.

Authors:  Astrid Fahrleitner-Pammer; Harald Dobnig; Claudia Piswanger-Soelkner; Christine Bonelli; Hans-Peter Dimai; Georg Leb; Barbara Obermayer-Pietsch
Journal:  Wien Klin Wochenschr       Date:  2003-05-15       Impact factor: 1.704

4.  Serum markers of bone turnover in dialyzed patients separated according to age.

Authors:  Alicja E Grzegorzewska; Monika Młot
Journal:  Int Urol Nephrol       Date:  2006       Impact factor: 2.370

5.  sRANKL/osteoprotegerin complex and biochemical markers in a cohort of male and female hemodialysis patients.

Authors:  K K Doumouchtsis; A I Kostakis; S K Doumouchtsis; M P Tziamalis; C Tsigris; M A Kostaki; D N Perrea
Journal:  J Endocrinol Invest       Date:  2007-10       Impact factor: 4.256

Review 6.  The TNF receptor superfamily: role in immune inflammation and bone formation.

Authors:  Xin Cheng; Masa Kinosaki; Ramachandran Murali; Mark I Greene
Journal:  Immunol Res       Date:  2003       Impact factor: 2.829

7.  Osteoprotegerin disrupts peripheral adhesive structures of osteoclasts by modulating Pyk2 and Src activities.

Authors:  Hongyan Zhao; Xuezhong Liu; Hui Zou; Nannan Dai; Lulian Yao; Xiao Zhang; Qian Gao; Wei Liu; Jianhong Gu; Yan Yuan; Jianchun Bian; Zongping Liu
Journal:  Cell Adh Migr       Date:  2016-01-08       Impact factor: 3.405

Review 8.  Receptor activator of nuclear factor kappaB ligand and osteoprotegerin regulation of bone remodeling in health and disease.

Authors:  Ann E Kearns; Sundeep Khosla; Paul J Kostenuik
Journal:  Endocr Rev       Date:  2007-12-05       Impact factor: 19.871

9.  Dexamethasone inhibits bone resorption by indirectly inducing apoptosis of the bone-resorbing osteoclasts via the action of osteoblastic cells.

Authors:  S Warabi; Y Tachibana; M Kumegawa; Y Hakeda
Journal:  Cytotechnology       Date:  2001-01       Impact factor: 2.058

10.  Mutations within the TNF-like core domain of RANKL impair osteoclast differentiation and activation.

Authors:  Taksum Cheng; Nathan J Pavlos; Cathy Wang; Jamie We-Yin Tan; Jian Ming Lin; Jillian Cornish; Ming-Hao Zheng; Jiake Xu
Journal:  Mol Endocrinol       Date:  2008-11-13
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.